References

1. Edward D, Dunbar C. Bioengineering of therapeutic aerosols. Annual Reviews of Bioengineering 4:93-107, 2002.

2. Patton J. Inhaled insulin. Adv Drug Deliv Rev 19:3-36, 1996.

3. Edwards DA, Hanes J, Caponetti G, Mintzes J, Hrkach J, Lotan N, Langer R. Large porous particles for pulmonary drug delivery. Science 276:1868-1871, 1997.

4. Rave KM, Heise T, Pfützner A, Stiner S, Heinemann L. Results of a dose-reponse study with a new pulmonary insulin formation and inhaler. Diabetes 49(Suppl. 1):305, 2000.

5. Choi WS, Murthy GGK, Edwards DA, Langer R, Klibanov AM. Inhalation delivery of proteins from ethanol suspensions. Proc Natl Acad Sci 98(20):11103-11107, 2001.

6. Tsapis N, Bennet D, Jackson B, Weitz D, Edwards DA. Trojan Particles: large porous nanoparticle systems for drug delivery. Proc Natl Acad Sci 99:12001 -12005, 2002.

7. American Diabetes Association. Diabetes: Vital Statistics, Alexandria, VA, 1996.

8. National Diabetes Data Group. Diabetes in America: Diabetes Data Compiled. Bethesda, MD: National Institutes of Health, 1985.

9. Deckert T, Poulsen JE, Larsen M. Prognosis of diabetics with diabetes onset before the age of thirty-one. Diabetologia 14:363-377, 1978.

10. Rave K, Heise T, Pfutzner A, Steiner S, Heinemann L. Results of a dose-response study with a new pulmonary insulin formulation and inhaler. 60th Scientific Sessions ADA; San Antonio, TX, 2000.

11. Heinemann L, Traut T, Heise T. Time-action profile of inhaled insulin. Diabet Med 14(1):63-72, 1997.

12. Osborn C, Batycky R, Verma A, Illerperuma A. Time-action profile of a new rapid-acting inhaled insulin with high biopotency. 61st Scientific Sessions ADA; Philadelphia, 1998.

13. Wolff RK. Safety of inhaled proteins for therapeutic use. J Aerosol Med 11:197-219, 1988.

14. Heinemann L, Klappoth W, Rave K, Hompesch B, Linkeschowa R, Heise T. Intra-individual variability of the metabolic effect of inhaled insulin together with an absorption enhancer. Diabetes Care 23(9):1343-1347, 2000.

15. Hilsted J, Madsbad S, Hvidberg A, Rasmussen MH, Krarup T, Ipsen H, Hansen B, Pedersen M, Djurup R, Oxenboll B. Intranasal insulin therapy: the clinical realities. Diabetologia 38:680-684, 1995.

16. Steiner S, Rave K, Heise T, Harzer O, Flacke F, Pfützner A, Heinemann L. Technosphere™/insulin: bioavailability and pharmacokinetic properties in healthy volunteers. Diabetologia 43(Suppl. 1):771, 2000.

17. Good WR, Powers MS, Campbell P, Schenkel L. A new transdermal delivery system for estradiol. J Control Release 2:89-97, 1985.

18. Santus GC, Baker RW. Transdermal enhancer patent literature. J Control Release 25(1-2):1-20, 1993.

19. Gregoriadis G. Engineering liposomes for drug discovery: progress and problems. Tibtech 13:527-537, 1995.

20. Deaton AT, Jones LD, Dunbar CA, Hickey AJ, Williams DM. Generation of gelatin aerosol particles from nebulized solutions as model drug carrier systems. Pharm Dev Technol 7(2):147-153, 2002.

21. Ben-Jebria A, Chen DH, Eskew ML, Vanbever R, Langer R, Edwards DA. Large porous particles for sustained protection from carbachol-induced bronchoconstric-tion in guinea pigs. Pharm Res 16(4):555-561, 1999.

22. Edwards DA, Ben-Jebria A, Langer R. Recent advances in pulmonary drug delivery using large, porous inhaled particles. J Appl Physiol 85(2):379-385, 1998.

23. French DL, Edwards DA, Niven RW. The influence of formulation on emission, deaggregation and deposition of dry powders for inhalation. J Aerosol Sci 27(5):769-783, 1996.

24. Kawaguchi H, Koiway N, Ohtsuka Y, Miyamoto M, Sasakawa S. Phagocytosis of latex-particles by leukocytes. 1. Dependence of phagocytosis on the size and surface-potential of particles. Biomaterials 7(1):61-66, 1986.

25. Edwards DA. Delivery of biological agents by aerosols. AIChE J 48(1):2-6, 2002.

Supplements For Diabetics

Supplements For Diabetics

All you need is a proper diet of fresh fruits and vegetables and get plenty of exercise and you'll be fine. Ever heard those words from your doctor? If that's all heshe recommends then you're missing out an important ingredient for health that he's not telling you. Fact is that you can adhere to the strictest diet, watch everything you eat and get the exercise of amarathon runner and still come down with diabetic complications. Diet, exercise and standard drug treatments simply aren't enough to help keep your diabetes under control.

Get My Free Ebook


Post a comment